OCGN · Ocugen Inc. Common Stock
View on chartInsiders & Stakes
| Junge Zhang Director | ▲ Buy | Option Exercise | 1,359,316 Shares held | 4/1/2026 | View profile |
| Shankar Musunuri Chief Executive Officer | ▼ Sell | Open Market | 1,088,035 Shares held | 9/9/2026 | View profile |
| Treerita Essalima Johnson-Greene Chief Financial Officer | ▲ Buy | Open Market | 521,000 Shares held | 6/15/2026 | View profile |
| Arun Upadhyay Chief Scientific Officer | ▼ Sell | Tax Withholding | 306,197 Shares held | 1/3/2025 | View profile |
| Ramesh Ramachandran Chief Accounting Officer | ▲ Buy | Grant | 209,100 Shares held | 1/2/2026 | View profile |
| Crespo Jessica CAO/SVP, Finance | ▲ Buy | Grant | 163,391 Shares held | 1/3/2023 | View profile |
| Subramanian Sanjay Chief Financial Officer | ▲ Buy | Grant | 161,125 Shares held | 1/3/2022 | View profile |
| Kompella Uday Director | ▼ Sell | Open Market | 154,416 Shares held | 11/2/2021 | View profile |
| Kirsten Castillo Director | ▲ Buy | Open Market | 75,000 Shares held | 11/22/2024 | View profile |
| Potti Manish Director | ▲ Buy | Option Exercise | 45,000 Shares held | 12/16/2021 | View profile |
| Prabhavathi Fernandes Director | ▲ Buy | Open Market | 10,000 Shares held | 11/26/2024 | View profile |
| Kumar Ramesh Director | ▼ Sell | Open Market | 0 Shares held | 10/6/2022 | View profile |
Transaction History
| Shankar Musunuri | ▼ Sell | Open Market | 468,727 | $525K | 9/9/2026 |
| Shankar Musunuri | ▼ Sell | Open Market | 57,264 | $64K | 9/9/2026 |
| Treerita Essalima Johnson-Greene | ▲ Buy | Open Market | 21,000 | $26K | 6/15/2026 |
| Junge Zhang | ▲ Buy | Option Exercise | 66,929 | $95K | 4/1/2026 |
| Junge Zhang | ▲ Buy | Option Exercise | 15,000 | $8K | 4/1/2026 |
| Junge Zhang | ▲ Buy | Option Exercise | 112,205 | $52K | 4/1/2026 |
| Shankar Musunuri | ▲ Buy | Grant | 3,123,201 | $0 | 1/2/2026 |
| Ramesh Ramachandran | ▲ Buy | Grant | 207,300 | $0 | 1/2/2026 |
| Arun Upadhyay | ▼ Sell | Tax Withholding | 41,633 | $37K | 1/3/2025 |
| Shankar Musunuri | ▼ Sell | Tax Withholding | 177,146 | $158K | 1/3/2025 |
| Prabhavathi Fernandes | ▲ Buy | Open Market | 10,000 | $9K | 11/26/2024 |
| Kirsten Castillo | ▲ Buy | Open Market | 25,000 | $23K | 11/22/2024 |
| Arun Upadhyay | ▼ Sell | Tax Withholding | 842 | $985 | 9/16/2024 |
| Arun Upadhyay | ▼ Sell | Tax Withholding | 917 | $1K | 6/17/2024 |
| Arun Upadhyay | ▼ Sell | Tax Withholding | 41,633 | $27K | 1/3/2024 |
| Shankar Musunuri | ▼ Sell | Tax Withholding | 180,204 | $118K | 1/3/2024 |
| Arun Upadhyay | ▼ Sell | Tax Withholding | 842 | $345 | 9/16/2023 |
| Arun Upadhyay | ▼ Sell | Tax Withholding | 917 | $468 | 6/16/2023 |
| Junge Zhang | ▲ Buy | Open Market | 200,278 | $100K | 6/14/2023 |
| Shankar Musunuri | ▲ Buy | Option Exercise | 100,000 | $33K | 2/16/2023 |
| Shankar Musunuri | ▼ Sell | Open Market | 100,000 | $108K | 2/16/2023 |
| Shankar Musunuri | ▲ Buy | Option Exercise | 100,000 | $51K | 1/17/2023 |
| Shankar Musunuri | ▼ Sell | Open Market | 100,000 | $128K | 1/17/2023 |
| Arun Upadhyay | ▼ Sell | Tax Withholding | 7,102 | $9K | 1/3/2023 |
| Crespo Jessica | ▼ Sell | Tax Withholding | 1,913 | $2K | 1/3/2023 |
| Shankar Musunuri | ▼ Sell | Tax Withholding | 37,877 | $47K | 1/3/2023 |
| Arun Upadhyay | ▲ Buy | Grant | 315,924 | $0 | 1/3/2023 |
| Crespo Jessica | ▲ Buy | Grant | 122,951 | $0 | 1/3/2023 |
| Shankar Musunuri | ▲ Buy | Grant | 1,475,410 | $0 | 1/3/2023 |
| Shankar Musunuri | ▼ Sell | Open Market | 95,809 | $137K | 12/16/2022 |
| Shankar Musunuri | ▲ Buy | Option Exercise | 95,809 | $49K | 12/16/2022 |
| Shankar Musunuri | ▲ Buy | Option Exercise | 100,000 | $51K | 10/14/2022 |
| Shankar Musunuri | ▼ Sell | Open Market | 100,000 | $166K | 10/14/2022 |
| Kumar Ramesh | ▲ Buy | Option Exercise | 4,500 | $2K | 10/6/2022 |
| Kumar Ramesh | ▼ Sell | Open Market | 4,500 | $8K | 10/6/2022 |
| Kirsten Castillo | ▲ Buy | Option Exercise | 42,000 | $12K | 8/11/2022 |
| Kirsten Castillo | ▼ Sell | Open Market | 42,000 | $122K | 8/11/2022 |
| Kumar Ramesh | ▲ Buy | Option Exercise | 7,500 | $4K | 7/18/2022 |
| Kumar Ramesh | ▼ Sell | Open Market | 7,500 | $19K | 7/18/2022 |
| Shankar Musunuri | ▲ Buy | Option Exercise | 150,000 | $50K | 7/14/2022 |
| Shankar Musunuri | ▼ Sell | Open Market | 150,000 | $408K | 7/14/2022 |
| Shankar Musunuri | ▲ Buy | Option Exercise | 125,000 | $41K | 5/13/2022 |
| Shankar Musunuri | ▼ Sell | Open Market | 125,000 | $240K | 5/13/2022 |
| Kumar Ramesh | ▲ Buy | Option Exercise | 7,500 | $4K | 4/18/2022 |
| Kumar Ramesh | ▼ Sell | Open Market | 7,500 | $21K | 4/18/2022 |
| Crespo Jessica | ▲ Buy | Grant | 22,940 | $0 | 3/18/2022 |
| Shankar Musunuri | ▲ Buy | Option Exercise | 81,823 | $27K | 3/16/2022 |
| Shankar Musunuri | ▼ Sell | Open Market | 81,823 | $217K | 3/16/2022 |
| Junge Zhang | ▲ Buy | Option Exercise | 39,000 | $20K | 3/3/2022 |
| Junge Zhang | ▲ Buy | Option Exercise | 49,000 | $90K | 3/3/2022 |
| Shankar Musunuri | ▲ Buy | Option Exercise | 90,000 | $30K | 2/14/2022 |
| Shankar Musunuri | ▼ Sell | Open Market | 90,000 | $337K | 2/14/2022 |
| Kumar Ramesh | ▲ Buy | Option Exercise | 7,500 | $4K | 1/18/2022 |
| Kumar Ramesh | ▼ Sell | Open Market | 7,500 | $31K | 1/18/2022 |
| Subramanian Sanjay | ▲ Buy | Grant | 125,534 | $0 | 1/3/2022 |
| Shankar Musunuri | ▲ Buy | Grant | 346,540 | $0 | 1/3/2022 |
| Potti Manish | ▲ Buy | Option Exercise | 13,500 | $7K | 12/16/2021 |
| Potti Manish | ▲ Buy | Option Exercise | 31,500 | $58K | 12/16/2021 |
| Shankar Musunuri | ▼ Sell | Open Market | 115,000 | $600K | 12/16/2021 |
| Junge Zhang | ▼ Sell | Other | 143,820 | $398K | 11/16/2021 |
| Junge Zhang | ▼ Sell | Other | 1,653 | $12K | 11/16/2021 |
| Shankar Musunuri | ▼ Sell | Open Market | 115,000 | $925K | 11/16/2021 |
| Junge Zhang | ▼ Sell | Open Market | 150,300 | $2.6M | 11/3/2021 |
| Kompella Uday | ▼ Sell | Open Market | 25,000 | $400K | 11/2/2021 |
| Potti Manish | ▼ Sell | Open Market | 63,429 | $956K | 11/2/2021 |
| Kirsten Castillo | ▼ Sell | Open Market | 15,000 | $225K | 11/2/2021 |
| Junge Zhang | ▼ Sell | Open Market | 149,700 | $2.4M | 11/2/2021 |
| Kompella Uday | ▼ Sell | Open Market | 25,000 | $351K | 11/1/2021 |
| Shankar Musunuri | ▲ Buy | Option Exercise | 115,367 | $59K | 11/1/2021 |
| Shankar Musunuri | ▼ Sell | Open Market | 115,367 | $1.6M | 11/1/2021 |
| Subramanian Sanjay | ▼ Sell | Open Market | 10,000 | $111K | 10/26/2021 |
| Kompella Uday | ▼ Sell | Open Market | 25,000 | $301K | 10/26/2021 |
| Kompella Uday | ▼ Sell | Open Market | 46,371 | $421K | 10/25/2021 |
| Kompella Uday | ▼ Sell | Open Market | 1,898 | $17K | 10/21/2021 |
| Kompella Uday | ▼ Sell | Open Market | 1,731 | $16K | 10/20/2021 |
| Kompella Uday | ▼ Sell | Open Market | 200,000 | $1.7M | 10/18/2021 |
| Kumar Ramesh | ▲ Buy | Option Exercise | 7,500 | $4K | 10/18/2021 |
| Kumar Ramesh | ▼ Sell | Open Market | 7,500 | $61K | 10/18/2021 |
| Shankar Musunuri | ▲ Buy | Option Exercise | 125,000 | $41K | 10/15/2021 |
| Shankar Musunuri | ▼ Sell | Open Market | 125,000 | $1.2M | 10/15/2021 |
| Subramanian Sanjay | ▲ Buy | Option Exercise | 7,990 | $17K | 10/15/2021 |
| Subramanian Sanjay | ▼ Sell | Open Market | 7,990 | $80K | 10/15/2021 |
| Shankar Musunuri | ▲ Buy | Option Exercise | 125,000 | $41K | 9/15/2021 |
| Shankar Musunuri | ▼ Sell | Open Market | 125,000 | $940K | 9/15/2021 |
| Subramanian Sanjay | ▲ Buy | Option Exercise | 30,000 | $10K | 8/16/2021 |
| Subramanian Sanjay | ▼ Sell | Open Market | 30,000 | $217K | 8/16/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Ocugen Secures Bahamas Approval for Gene Therapy OCU400
Ocugen received provisional approval from the Bahamas regulator to supply its gene‑therapy OCU400 for retinitis pigmentosa. The company will provide the treatment through an expanded access program and aims to treat the first patient within 90 days. The approval also grants priority designation under the Bahamas Longevity and Regenerative Therapies Act. This development may broaden global access for Ocugen’s therapy.
Ocugen Secures Bahamas Approval for Gene Therapy OCU400. Ocugen received provisional approval from the Bahamas regulator to supply its gene‑therapy OCU400 for retinitis pigmentosa. The company will provide the treatment through an expanded access program and aims to treat the first patient within 90 days. The approval also grants priority designation under the Bahamas Longevity and Regenerative Therapies Act. This development may broaden global access for Ocugen’s therapy.